$4.35
0.081.87%
Pre-Market: Jul 19, 4:17 PM EDT
15 minutes delayed
Comments
Loading...
Fate Therapeutics
FATENASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Fate Therapeutics (NASDAQ:FATE) Stock, Analyst Ratings, Price Targets, Forecasts
Fate Therapeutics Inc has a consensus price target of $10.75 based on the ratings of 24 analysts. The high is $62 issued by Morgan Stanley on December 15, 2021. The low is $4 issued by Goldman Sachs on January 9, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, HC Wainwright & Co., and Canaccord Genuity on June 17, 2024, May 16, 2024, and May 10, 2024, respectively. With an average price target of $6.67 between Piper Sandler, HC Wainwright & Co., and Canaccord Genuity, there's an implied 53.26% upside for Fate Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
Canaccord Genuity
BMO Capital
Wedbush
1calculated from analyst ratings
Analyst Ratings for Fate Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/17/2024 | Buy Now | 37.93% | Piper Sandler | Edward Tenthoff | $4 → $6 | Upgrade | Neutral → Overweight | Get Alert |
| 05/16/2024 | Buy Now | 14.94% | HC Wainwright & Co. | Raghuram Selvaraju | $7 → $5 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 106.9% | Canaccord Genuity | Bill Maughan | $11 → $9 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 37.93% | BMO Capital | Etzer Darout | $7 → $6 | Maintains | Market Perform | Get Alert |
| 05/10/2024 | Buy Now | 14.94% | Wedbush | David Nierengarten | $7 → $5 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | -8.05% | Piper Sandler | Edward Tenthoff | $7 → $4 | Maintains | Neutral | Get Alert |
| 05/06/2024 | Buy Now | 60.92% | Wedbush | David Nierengarten | → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 04/23/2024 | Buy Now | 60.92% | Wedbush | David Nierengarten | → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 04/11/2024 | Buy Now | — | Needham | Gil Blum | — | Reiterates | → Hold | Get Alert |
| 03/28/2024 | Buy Now | 37.93% | B of A Securities | Tazeen Ahmad | $2 → $6 | Maintains | Underperform | Get Alert |
| 03/19/2024 | Buy Now | 60.92% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | Neutral → Neutral | Get Alert |
| 02/27/2024 | Buy Now | 60.92% | Morgan Stanley | Michael Ulz | $3 → $7 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | Buy Now | 60.92% | BMO Capital | Etzer Darout | $6 → $7 | Maintains | Market Perform | Get Alert |
| 02/27/2024 | Buy Now | 129.89% | Barclays | Peter Lawson | $6 → $10 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 60.92% | Wedbush | David Nierengarten | $3 → $7 | Maintains | Neutral | Get Alert |
| 02/27/2024 | Buy Now | — | Oppenheimer | Matthew Biegler | — | Reiterates | Perform → Perform | Get Alert |
| 11/20/2023 | Buy Now | 83.91% | Mizuho | Mara Goldstein | $12 → $8 | Maintains | Buy | Get Alert |
| 11/13/2023 | Buy Now | -31.03% | Morgan Stanley | Michael Ulz | $5 → $3 | Maintains | Equal-Weight | Get Alert |
| 11/09/2023 | Buy Now | 37.93% | BMO Capital | Etzer Darout | $5.4 → $6 | Maintains | Market Perform | Get Alert |
| 11/09/2023 | Buy Now | -31.03% | Wedbush | David Nierengarten | $6 → $3 | Maintains | Neutral | Get Alert |
| 11/09/2023 | Buy Now | 14.94% | Wells Fargo | Yanan Zhu | $6 → $5 | Maintains | Equal-Weight | Get Alert |
| 09/07/2023 | Buy Now | 14.94% | Cantor Fitzgerald | Li Watsek | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 08/16/2023 | Buy Now | 60.92% | Truist Securities | Robyn Karnauskas | → $7 | Reiterates | Hold → Hold | Get Alert |
| 08/10/2023 | Buy Now | 14.94% | Morgan Stanley | Michael Ulz | $8 → $5 | Maintains | Equal-Weight | Get Alert |
| 08/10/2023 | Buy Now | 37.93% | Barclays | Peter Lawson | $12 → $6 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 24.14% | BMO Capital | Etzer Darout | $6 → $5.4 | Maintains | Market Perform | Get Alert |
| 08/09/2023 | Buy Now | 129.89% | EF Hutton | Tony Butler | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 60.92% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | → Neutral | Get Alert |
| 05/04/2023 | Buy Now | 14.94% | Stifel | Benjamin Burnett | $5.3 → $5 | Maintains | Hold | Get Alert |
| 05/04/2023 | Buy Now | 14.94% | Cantor Fitzgerald | Li Watsek | $8 → $5 | Maintains | Neutral | Get Alert |
| 03/27/2023 | Buy Now | 37.93% | Wells Fargo | Yanan Zhu | → $6 | Assumes | → Equal-Weight | Get Alert |
| 03/02/2023 | Buy Now | 129.89% | Citigroup | Yigal Nochomovitz | $9 → $10 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | 129.89% | EF Hutton | Tony Butler | → $10 | Reiterates | → Buy | Get Alert |
| 01/24/2023 | Buy Now | 60.92% | HC Wainwright & Co. | Robert Burns | $115 → $7 | Downgrade | Buy → Neutral | Get Alert |
| 01/09/2023 | Buy Now | -8.05% | Goldman Sachs | Andrea Tan | $10 → $4 | Maintains | Sell | Get Alert |
| 01/06/2023 | Buy Now | 83.91% | Morgan Stanley | Michael Ulz | $35 → $8 | Maintains | Equal-Weight | Get Alert |
| 01/06/2023 | Buy Now | -8.05% | B of A Securities | Tazeen Ahmad | $72 → $4 | Downgrade | Buy → Underperform | Get Alert |
| 01/06/2023 | Buy Now | 21.84% | Stifel | Benjamin Burnett | $107 → $5.3 | Downgrade | Buy → Hold | Get Alert |
| 01/06/2023 | Buy Now | 129.89% | EF Hutton | Tony Butler | $16 → $10 | Maintains | Buy | Get Alert |
| 01/06/2023 | Buy Now | 60.92% | Wedbush | David Nierengarten | → $7 | Downgrade | Outperform → Neutral | Get Alert |
| 01/06/2023 | Buy Now | 129.89% | SVB Leerink | Daina Graybosch | $62 → $10 | Maintains | Outperform | Get Alert |
| 01/06/2023 | Buy Now | — | Cowen & Co. | Tyler Van Buren | — | Downgrade | Outperform → Market Perform | Get Alert |
| 01/06/2023 | Buy Now | 175.86% | Piper Sandler | Edward Tenthoff | $71 → $12 | Downgrade | Overweight → Neutral | Get Alert |
| 01/06/2023 | Buy Now | 60.92% | BMO Capital | Etzer Darout | $20 → $7 | Downgrade | Outperform → Market Perform | Get Alert |
| 01/06/2023 | Buy Now | 60.92% | Truist Securities | Robyn Karnauskas | $46 → $7 | Downgrade | Buy → Hold | Get Alert |
| 01/05/2023 | Buy Now | 267.82% | EF Hutton | Tony Butler | → $16 | Initiates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | — | Guggenheim | Michael Schmitz | — | Downgrade | Buy → Neutral | Get Alert |
| 12/22/2022 | Buy Now | — | Oppenheimer | Matthew Biegler | — | Downgrade | Outperform → Perform | Get Alert |
| 12/15/2022 | Buy Now | 129.89% | Goldman Sachs | Andrea Tan | → $10 | Initiates | → Sell | Get Alert |
| 12/13/2022 | Buy Now | 957.47% | Truist Securities | Robyn Karnauskas | $51 → $46 | Maintains | Buy | Get Alert |
| 12/13/2022 | Buy Now | 1325.29% | SVB Leerink | Daina Graybosch | $64 → $62 | Maintains | Outperform | Get Alert |
| 11/16/2022 | Buy Now | 1739.08% | Citigroup | Yigal Nochomovitz | $87 → $80 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 934.48% | Cantor Fitzgerald | Li Watsek | $98 → $45 | Assumes | → Overweight | Get Alert |
| 09/09/2022 | Buy Now | 704.6% | Morgan Stanley | Michael Ulz | $45 → $35 | Maintains | Equal-Weight | Get Alert |
| 07/28/2022 | Buy Now | — | Needham | Gil Blum | — | Initiates | → Hold | Get Alert |
| 07/12/2022 | Buy Now | 980.46% | BMO Capital | Etzer Darout | $50 → $47 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/11/2022 | Buy Now | 980.46% | BMO Capital | Etzer Darout | → $47 | Upgrade | Market Perform → Outperform | Get Alert |
| 06/03/2022 | Buy Now | 543.68% | Baird | Jack Allen | → $28 | Initiates | → Neutral | Get Alert |
| 05/23/2022 | Buy Now | 1532.18% | Piper Sandler | Edward Tenthoff | $113 → $71 | Maintains | Overweight | Get Alert |
| 05/05/2022 | Buy Now | 934.48% | Morgan Stanley | Michael Ulz | $52 → $45 | Maintains | Equal-Weight | Get Alert |
| 03/04/2022 | Buy Now | 2543.68% | HC Wainwright & Co. | Robert Burns | $122 → $115 | Maintains | Buy | Get Alert |
| 12/15/2021 | Buy Now | 1325.29% | Morgan Stanley | — | — | Maintains | Equal-Weight | Get Alert |
| 12/15/2021 | Buy Now | 1601.15% | Wedbush | David Nierengarten | — | Upgrade | Neutral → Outperform | Get Alert |
| 12/15/2021 | Buy Now | 2704.6% | HC Wainwright & Co. | Robert Burns | — | Maintains | Buy | Get Alert |
| 12/07/2021 | Buy Now | — | Cowen & Co. | Tyler Van Buren | — | Initiates | → Outperform | Get Alert |
| 11/09/2021 | Buy Now | 1900% | Citigroup | Yigal Nochomovitz | — | Upgrade | Neutral → Buy | Get Alert |
| 11/08/2021 | Buy Now | 2543.68% | SVB Leerink | Daina Graybosch | — | Maintains | Outperform | Get Alert |
| 08/26/2021 | Buy Now | 1670.11% | Morgan Stanley | Michael Ulz | — | Initiates | → Equal-Weight | Get Alert |
| 08/05/2021 | Buy Now | 2612.64% | SVB Leerink | Daina Graybosch | — | Maintains | Outperform | Get Alert |
| 08/05/2021 | Buy Now | 2681.61% | HC Wainwright & Co. | Robert Burns | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Fate Therapeutics (FATE) stock?
The latest price target for Fate Therapeutics (NASDAQ:FATE) was reported by Piper Sandler on June 17, 2024. The analyst firm set a price target for $6.00 expecting FATE to rise to within 12 months (a possible 37.93% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fate Therapeutics (FATE)?
The latest analyst rating for Fate Therapeutics (NASDAQ:FATE) was provided by Piper Sandler, and Fate Therapeutics upgraded their overweight rating.
When was the last upgrade for Fate Therapeutics (FATE)?
The last upgrade for Fate Therapeutics Inc happened on June 17, 2024 when Piper Sandler raised their price target to $6. Piper Sandler previously had a neutral for Fate Therapeutics Inc.
When was the last downgrade for Fate Therapeutics (FATE)?
The last downgrade for Fate Therapeutics Inc happened on January 24, 2023 when HC Wainwright & Co. changed their price target from $115 to $7 for Fate Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Fate Therapeutics (FATE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fate Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fate Therapeutics was filed on June 17, 2024 so you should expect the next rating to be made available sometime around June 17, 2025.
Is the Analyst Rating Fate Therapeutics (FATE) correct?
While ratings are subjective and will change, the latest Fate Therapeutics (FATE) rating was a upgraded with a price target of $4.00 to $6.00. The current price Fate Therapeutics (FATE) is trading at is $4.35, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.